Effects of heart disease on depression treatment: Results from the COMED study

General Hospital Psychiatry

Volumn 34, Issue 1, 2012, Pages 24-34

  Kerber, Kevin Brian ^a   Wisniewski, Stephen R ^b   Luther, James F ^b   Leuchter, Andrew F ^c   D'Empaire, Inna ^d   Trivedi, Madhukar H ^e   Rush, A John ^f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

CO MED study; Depression treatment; Heart disease

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; MIRTAZAPINE; VENLAFAXINE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART DISEASE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SOCIAL INTERACTION; STUDY DESIGN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84855345949     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.08.018     Document Type: Article

References (50)

1. Rudisch B., Nemeroff C.B. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003, 54:227-240.
2. Nicholson A., Kuper H., Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146,538 participants in 54 observational studies. Eur Heart J 2006, 27:2763-2774.
3. Kendler K.S., Gardner C.O., Fiske A., Gatz M. Major depression and coronary artery disease in the Swedish Twin Registry. Arch Gen Psychiatry 2009, 66:857-863.
4. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
5. Simon G.E., Von Korff M., Lin E. Clinical and functional outcomes of depression treatment in patients with and without chronic medical illness. Psychol Med 2005, 35:271-279.
6. Alexopoulos G.S., Kiosses D.N., Murphy C., Heo M. Executive dysfunction, heart disease burden, and remission of geriatric depression. Neuropsychopharmacology 2004, 29:2278-2284.
7. Krishnan K.R., Hays J.C., Blazer D.G. MRI-defined vascular depression. Am J Psychiatry 1997, 154:497-501.
8. Alexopoulos G.S., Meyers B.S., Young R.C., Campbell S., Silbersweig D., Charlson M. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997, 54:915-922.
9. Baldwin R., Jeffries S., Jackson D., et al. Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med 2004, 34:125-136.
10. Pohle K., Domschke K., Roehrs T., Arolt V., Baune B.T. Medical comorbidity affects antidepressant treatment response in patients with melancholic depression. Psychother Psychosom 2009, 78:359-363.
11. Koike A.K., Unutzer J., Wells K.B. Improving the care for depression in patients with comorbid medical illness. Am J Psychiatry 2002, 159:1738-1745.
12. Harpole L.H., Williams J.W., Olsen M.K., et al. Improving depression outcomes in older adults with comorbid medical illness. Gen Hosp Psychiatry 2005, 27:4-12.
13. Iosifescu D.V., Clementi-Craven N., Fraguas R., et al. Cardiovascular risk factors may moderate pharmacological treatments in major depressive disorder. Psychosom Med 2005, 67:703-706.
14. Sonawalla S.B., Papakostas G.I., Petersen T.J., et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002, 43(4):310-316.
15. Miller M.D., Lenze E.J., Dew M.A., et al. Effect of cerebrovascular risk factors on depression treatment outcomes in later life. Am J Geriatr Psychiatry 2002, 10:592-598.
16. de Jonge P., Honig A., van Melle J.P., et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 2007, 164(9):1371-1378.
17. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes: a single-blind randomized study. Am J Psychiatry [in press].
18. Kroenke K., Spitzer R.L., Williams J.B.W. The PHQ-9. Validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
19. Kroenke K., Spitzer R.L., Williams J.B. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003, 41(11):1284-1292.
20. American Psychiatric Association Diagnostic and statistical manual of mental disorder 2000, American Psychiatric Press, Washington (DC). 4th ed., text rev.
21. Hamilton M. A rating scale for depression. J Neurol Neursurg Psychiatry 1960, 23:56-61.
22. Fava M., Rush A.J., Alpert J.E., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008, 165(3):342-351.
23. Zimmerman M., Mattia J.I. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry 2001, 42(3):175-189.
24. Zimmerman M., Mattia J.I. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry 2001, 58(8):787-794.
25. Rush A.J., Zimmerman M., Wisniewski S.R., et al. Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. J Affect Disord 2005, 87(7):43-55.
26. Trivedi MH, et al. Concise health risk tracking (CHRT) scale: a brief self and clinician rating of suicidal risk. (Submitted for publication).
27. Altman E.G., Hedeker D., Peterson J.L., Davis J.M. The Altman Self-Rating Mania Scale. Biol Psychiatry 1997, 42(10):948-955.
28. Fava M., Iosifescu D.V., Pedrelli P., Baer L. Reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. Psychother Psychosom 2009, 78(2):91-97. [Epub 2009 Feb 13].
29. Sangha O., Stucki G., Liang M.H., Fossel A.H., Katz J.N. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003, 49(2):156-163.
30. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
31. Trivedi M.H., Daly E.J. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007, 88(Suppl 2):S61-S71.
32. Trivedi M.H., Rush A.J., Gaynes B.N., et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007, 32(12):2479-2489.
33. Rush A.J., Trivedi M.H., Ibrahim H.M., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54(5):573-583. [Erratum p. 585].
34. Trivedi M.H., Rush A.J., Ibrahim H.M., et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004, 34(1):73-82.
35. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996, 26(3):477-486.
36. Wisniewski S.R., Rush A.J., Balasubramani G.K., Trivedi M.H., Nierenberg A.A. Self-rated global measure of the Frequency, Intensity, and Burden of Side Effects. J Psychiatr Pract 2006, 12(2):71-79.
37. Wisniewski S.R., Eng H., Meloro L., et al. Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clin Trials 2004, 1(4):387-398.
38. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001, 62(Suppl 18):4-11.
39. Papakostas G.I., Petersen T.J., Kinrys G., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005, 66(10):1326-1330.
40. Leuchter A.F., Lesser I.M., Trivedi M.H., et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008, 14(5):271-280.
41. McGrath P.J., Stewart J.W., Fava M., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: STAR*D report. Am J Psychiatry 2006, 163(9):1531-1541.
42. Rush A.J., Bernstein I.H., Trivedi M.H., et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006, 59(6):493-501. [Epub 2005 Sep 30].
43. Rush A.J., Carmody T.J., Reimitz P.E. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000, 9:45-59.
44. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4(5):353-365.
45. Mundt J.C., Marks I.M., Shear M.K., Greist J.H. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 2002, 180:461-464.
46. Frisch M.B. Manual and treatment guide for the Quality of Life Inventory 1994, National Computer Systems, Inc., Minneapolis, MN.
47. Frisch M.B., Clark M.P., Rouse S.V., et al. Predictive and treatment validity of life satisfaction and the Quality of Life Inventory. Assessment 2005, 12(1):66-78.
48. Levine J., Schooler N.R. SAFTEE: a technique for the Systematic Assessment of Side Effects in clinical trials. Psychopharmacol Bull 1986, 22(2):343-381.
49. Levine J., Schooler N.R. General versus specific inquiry with SAFTEE. J Clin Psychopharmacol 1992, 12(6):448.
50. Bryan C., Songer T., Brooks, et al. The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry 2010, 32:33-41.